However, it seems that long-term L-carnitine intake eventually converts to a metabolite called trimethylamine N-oxide (TMAO) (9799), and increased circulating levels of this metabolite can increase the prevalence of diabetes (54% per 5 mol/L increment of plasma TMAO) (100), nonetheless one study showed that increased TMAO plasma level by 30 mol/L after 24 weeks of L-carnitine supplementation was not related to glucose, insulin and HOMA-IR levels changes (97)
Keywords : GLP-1 receptor agonists, FDG PET-CT, oncology imaging, metabolic disorders, diabetes, weight management, diagnostic imaging, molecular imaging, nuclear medicine, pharmacotherapy impact, cancer staging, imaging artifacts
Capturing VCP: another molecular piece in the als jigsaw puzzle
Alternatively, enzyme responsive intelligent delivery systems can be used to release drugs from tablets under the action of specific enzymes
Michelle R